Bristol-Myers Squibb Company (BMY)
Is Bristol Myers Squibb a Good Dividend Stock to Buy Now?
Bristol Myers Squibb lowered its earnings outlook earlier this year to account for recent acquisitions. One of Bristol Myers Squibb's top-selling drugs, Revlimid, has already lost patent-protected market exclusivity.
Bristol-Myers Squibb Earnings Reinforces Our Thesis
Bristol-Myers Squibb Company stock crossed $50/share after strong earnings. The company saw 18% YoY revenue growth in 2Q 2024. Bristol-Myers has a strong pipeline with potential for future growth, focusing on debt reduction and shareholder returns.
Is Bristol-Myers Squibb's Stock Rally Justified? Bull Vs. Bear Analysts On Q2 Earnings
Bristol-Myers Squibb Co BMY on Friday reported upbeat second-quarter results.
Pharma Giant's Shares Up After Impressive Q2 Earnings Release
Bristol-Myers Squibb NYSE: BMY is in the healthcare sector and is the 10th largest pharmaceutical firm in the world by market capitalization. The company released Q2 2024 financial results on July 26, 2024.
Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks With Over 3% Dividend Yields
During times of turbulence and uncertainty in the markets, even when markets are at all-time highs, many investors turn to dividend-yielding stocks.
This Bristol-Myers Squibb Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
6 Blue Chip Dividend Stock Bargains to Buy Now That All Yield 5% and More
24/7 Wall St. Insights Dividend stocks will outperform when the Federal Reserve starts to lower rates in September.
Bristol Myers Squibb Shows Resilience Amid Patent Expiry Challenges (Rating Upgrade)
Bristol Myers Squibb's Q2 2024 revenue increased 9% year-over-year, reaching $12.2 billion. Newer drugs like Reblozyl and Opdualag demonstrated strong revenue growth in Q2, 2024. Despite facing patent cliffs, BMS's up-and-coming assets like Reblozyl, Breyanzi, and KarXT for schizophrenia offer promising future revenue potential.
2 High-Yield Dividend Stocks That Could Shine in 2025
Dividend yields have historically been a strong predictor of stock returns over long periods. Current market conditions could be ripe for a rally in high-yield equities.
Bristol-Myers Squibb: Q2 Earnings Look Like An Inflection Point
Bristol-Myers Squibb had a strong Q2 earnings report, backed by strong momentum in both legacy and new products. The management has boosted its guidance for the remainder of 2024, enhancing confidence in the safety of the stock's stellar 5% dividend yield. Seasonality trends suggest that the stock usually performs much better in the second half of a year.
Why Bristol Myers Squibb Jumped Nearly 10% on Friday
The drugmaker's newest therapies are seeing unexpectedly strong sales growth. Its legacy drug portfolio, meanwhile, is still a solid cash cow.
Bristol-Myers Squibb Company (BMY) Q2 2024 Earnings Call Transcript
Bristol-Myers Squibb Company (NYSE:BMY ) Q2 2024 Earnings Conference Call July 26, 2024 8:00 AM ET Company Participants Tim Power - Vice President, Head of Investor Relations Chris Boerner - Board Chair and Chief Executive Officer David Elkins - Executive Vice President and Chief Financial Officer Adam Lenkowsky - Executive Vice President, Chief Commercialization Officer Samit Hirawat - Executive Vice President, Chief Medical Officer, Global Drug Development Conference Call Participants Chris Schott - JPMorgan Luisa Hector - Berenberg Chris Shibutani - Goldman Sachs Tim Anderson - Wolfe Research Evan Seigerman - BMO Capital Markets Carter Gould - Barclays Seamus Fernandez - Guggenheim Securities Terence Flynn - Morgan Stanley Mohit Bansal - Wells Fargo David Risinger - Leerink Partners Steve Scala - TD Cowen Trung Huynh - UBS Matthew Phipps - William Blair Olivia Brayer - Cantor Fitzgerald Steve Chesney - Redburn Atlantic James Shin - Deutsche Bank Kripa Devarakonda - Truist Securities Sean McCutcheon - Raymond James Alexandria Hammond - Bank of America Operator Good day and welcome to the Bristol Myers Squibb Second Quarter 2024 Earnings Conference Call. All participants will be in listen-only mode.
